

Maurizio MEMO

Name: Memo Maurizio

Date and place of birth: April 26, 1953, Cagliari, Italy

Position title: Full Professor of Pharmacology

Address: Department of Biomedical Sciences and Biotechnologies, University of Brescia Medical School, Viale Europa 11, 25123 Brescia

Position and employment

2000- present Full Professor of Pharmacology, University of Brescia, Italy

1988-2000 Associate Professor of Pharmacology, University of Brescia, Italy

1988-1990 Visiting Ass. Prof. Pharmacology, Georgetown University Medical School, Washington D.C., USA

1983-1988 Researcher in Pharmacology, University of Cagliari, Italy

1980-1982 Research fellow, at the National Heart, Lung and Blood Institute, Section on Biochemical

Pharmacology, NIH, Bethesda, MD, USA

Education

1980 Residency in Pharmacology, University of Milan

1977 Graduated in Chemistry and Pharmaceutical Technology, University of Cagliari

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIP

2007 Associated Editor of "BMC Pharmacology"

2005 Member of the Editorial Board of "CNS Drug Review"

2003 Owner of a patent entitled "Method for early identification of Alzheimer's Disease"

2002 Owner of a patent entitled "Useful compound for the treatment of neurodegenerative disease"

2000- Chief Molecular Neuropharmacology Laboratory, University of Brescia, Italy

1998- Associate Editor of "Functional Neurology"

1995- Founder and Vice-President of the European School of Molecular Medicine

1994- Professor Faculty PhD program in Neuroscience

1991- Founder and President of the Italian Group of Molecular Neurobiology

Author of more than 200 full scientific papers all published in recognized international Journals. Organizer of 12 International Symposia. Principal Investigator of several research projects sponsored by national and international Institutions and supervisor of a research group with a total of 12 post-doc.s, PhD students and technicians.

Winner of the Roussel Price for Gerontological Research (1987)

Winner of the Sandoz Foundation Price (1994).

Main interest: neuropharmacology, role of Dopamine systems in schizophrenia and Parkinson's disease, molecular mechanisms of neurodegeneration, genetic and molecular risk factors for Alzheimer's disease.

List of relevant publications

Denis-Donini S, Dellarole A, Crociara P, Francese MT, Bortolotto V, Quadrato G, Canonico PL, Orsetti M, Ghi P, **Memo M**, Bonini SA, Ferrari-Toninelli G, Grilli M.

Impaired adult neurogenesis associated with short-term memory defects in NF-kappaB p50-deficient mice. *J Neurosci*. 2008 Apr 9;28(15):3911-9.

Lanni C, Racchi M, Mazzini G, Ranzenigo A, Polotti R, Sinforiani E, Olivari L, Barcikowska M, Styczynska M, Kuznicki J, Szybinska A, Govoni S, **Memo M**, Uberti D.

Conformationally altered p53: a novel Alzheimer's disease marker? *Mol Psychiatry*. 2008 Jun;13(6):641-7.

Uberti D, Ferrari-Toninelli G, Bonini SA, Sarnico I, Benarese M, Pizzi M, Benussi L, Ghidoni R, Binetti G, Spano P, Facchetti F, **Memo M**.

Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity.

Neuropsychopharmacology. 2007 Apr;32(4):872-80. Epub 2006 Aug 16.

Francisconi S, Codenotti M, Ferrari-Toninelli G, Uberti D, **Memo M**.

Preservation of DNA integrity and neuronal degeneration.

Brain Res Brain Res Rev. 2005 Apr;48(2):347-51.

Uberti D, Carsana T, Bernardi E, Rodella L, Grigolato P, Lanni C, Racchi M, Govoni S, **Memo M**

Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. *J Cell Sci*. 2002 Aug 1;115(Pt 15):3131-8..

Copani A, Uberti D, Sortino MA, Bruno V, Nicoletti F, **Memo M**.

Activation of cell-cycle-associated proteins in neuronal death: a mandatory or dispensable path?

Trends Neurosci. 2001 Jan;24(1):25-31

Grilli M, **Memo M**.

Nuclear factor-kappaB/Rel proteins: a point of convergence of signalling pathways relevant in neuronal function and dysfunction.

Biochem Pharmacol. 1999 Jan 1;57(1):1-7

Grilli M, Pizzi M, **Memo M**, Spano P.

Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation.

Science. 1996 Nov 22;274(5291):1383-5.

Liberini P, Valerio A, **Memo M**, Spano PF.

Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?

Trends Pharmacol Sci. 1996 Apr;17(4):155-60.

Memo M, Kleinman JE, Hanbauer I.

Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics.

Science. 1983 Sep 23;221(4617):1304-7.